{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:34:15Z","timestamp":1792679655390,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK|Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1050"],"award-info":[{"award-number":["KKL1050"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.15252\/emmm.201707567","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T20:25:31Z","timestamp":1497990331000},"page":"1067-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Oncolytic adenovirus expressing bispecific antibody targets T\u2010cell cytotoxicity in cancer biopsies"],"prefix":"10.1038","volume":"9","author":[{"given":"Joshua D","family":"Freedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Psallidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Spiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-2282","authenticated-orcid":false,"given":"Nikolaos","family":"Kanellakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ashfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry D","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0841","authenticated-orcid":false,"given":"Leonard W","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"BFEMMM201707567_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship between CD107a expression and cytotoxic activity. Cell Immunol 254: 149\u2013154","journal-title":"Cell Immunol"},{"key":"BFEMMM201707567_CR2","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C (2009) Bispecific T\u2010cell engaging antibodies for cancer therapy. Cancer Res 69: 4941\u20134944","journal-title":"Cancer Res"},{"key":"BFEMMM201707567_CR3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et\u00a0al (2008) Tumor regression in cancer patients by very low doses of a T cell\u2010engaging antibody. Science 321: 974\u2013977","journal-title":"Science"},{"key":"BFEMMM201707567_CR4","first-page":"77","volume":"97","author":"A Boyum","year":"1968","unstructured":"Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77\u201389","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"BFEMMM201707567_CR5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","volume":"43","author":"K Brischwein","year":"2006","unstructured":"Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T et\u00a0al (2006) MT110: a novel bispecific single\u2010chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43: 1129\u20131143","journal-title":"Mol Immunol"},{"key":"BFEMMM201707567_CR6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","volume":"30","author":"K Brischwein","year":"2007","unstructured":"Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et\u00a0al (2007) Strictly target cell\u2010dependent activation of T cells by bispecific single\u2010chain antibody constructs of the BiTE class. J Immunother 30: 798\u2013807","journal-title":"J Immunother"},{"key":"BFEMMM201707567_CR7","first-page":"lv361","volume":"25","author":"EGMM Calvo","year":"2014","unstructured":"Calvo EGMM, Cubillo A, Machiels J, Rottey S, Mardjuadi F, Geboes K, Salazar RBJ, Ellis C, Fisher K, Blanc C (2014) A phase 1 study of enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus, administered intravenously \u2013 analysis of dose expansion and repeat cycle cohorts in patients with metastatic colorectal cancer (mCRC). Ann Oncol 25: lv361\u2013lv372","journal-title":"Ann Oncol"},{"key":"BFEMMM201707567_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","volume":"21","author":"Y Di","year":"2014","unstructured":"Di Y, Seymour L, Fisher K (2014) Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther 21: 440\u2013443","journal-title":"Gene Ther"},{"key":"BFEMMM201707567_CR10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA (2002) Extremely potent, rapid and costimulation\u2010independent cytotoxic T\u2010cell response against lymphoma cells catalyzed by a single\u2010chain bispecific antibody. Int J Cancer 100: 690\u2013697","journal-title":"Int J Cancer"},{"key":"BFEMMM201707567_CR11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","volume":"4","author":"A Dyer","year":"2017","unstructured":"Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jakeman P, Chia SL, Brown A, Silva MA et\u00a0al (2017) Oncolytic group B adenovirus enadenotucirev mediates non\u2010apoptotic cell death with membrane disruption and release of inflammatory mediators. Mol Ther Oncolytics 4: 18\u201330","journal-title":"Mol Ther Oncolytics"},{"key":"BFEMMM201707567_CR200","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias\u2010Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic Adenoviral Delivery of an EGFR\u2010Targeting T\u2010cell Engager Improves Antitumor Efficacy. Cancer Res 77: 2052\u20132063","journal-title":"Cancer Res"},{"key":"BFEMMM201707567_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39: 44\u201351","journal-title":"Curr Opin Immunol"},{"key":"BFEMMM201707567_CR201","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6: 343\u2013345","journal-title":"Nat Methods"},{"key":"BFEMMM201707567_CR14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.seminoncol.2016.10.005","volume":"43","author":"C Grigg","year":"2016","unstructured":"Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y (2016) Talimogene laherparepvec (T\u2010Vec) for the treatment of melanoma and other cancers. Semin Oncol 43: 638\u2013646","journal-title":"Semin Oncol"},{"key":"BFEMMM201707567_CR15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","volume":"15","author":"TD de Gruijl","year":"2015","unstructured":"de Gruijl TD, Janssen AB, van Beusechem VW (2015) Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 15: 959\u2013971","journal-title":"Expert Opin Biol Ther"},{"key":"BFEMMM201707567_CR16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.cgt.7700542","volume":"9","author":"TW Hermiston","year":"2002","unstructured":"Hermiston TW, Kuhn I (2002) Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9: 1022\u20131035","journal-title":"Cancer Gene Ther"},{"key":"BFEMMM201707567_CR17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth S, Di Y, Bauzon M, Lei J, Duffy M, Alvis S, Champion B, Lieber A, Hermiston T, Seymour L et\u00a0al (2017) Pre\u2010clinical safety studies of enadenotucirev, a chimeric group B human\u2010specific oncolytic adenovirus. Mol Ther Oncolytics 5: 62\u201374","journal-title":"Mol Ther Oncolytics"},{"key":"BFEMMM201707567_CR18","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/onc.2010.335","volume":"29","author":"CK Ingemarsdotter","year":"2010","unstructured":"Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA (2010) Low\u2010dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29: 6051\u20136063","journal-title":"Oncogene"},{"key":"BFEMMM201707567_CR19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jim.2008.02.008","volume":"334","author":"M Karlsson","year":"2008","unstructured":"Karlsson M, Nilsson O, Thorn M, Winqvist O (2008) Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry. J Immunol Methods 334: 122\u2013133","journal-title":"J Immunol Methods"},{"key":"BFEMMM201707567_CR20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","volume":"94","author":"BA Keller","year":"2016","unstructured":"Keller BA, Bell JC (2016) Oncolytic viruses\u2010immunotherapeutics on the rise. J Mol Med (Berl) 94: 979\u2013991","journal-title":"J Mol Med (Berl)"},{"key":"BFEMMM201707567_CR21","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A et\u00a0al (2012) Immunopharmacologic response of patients with B\u2010lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2010engaging CD19\/CD3\u2010bispecific BiTE antibody blinatumomab. Blood 119: 6226\u20136233","journal-title":"Blood"},{"key":"BFEMMM201707567_CR22","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K et\u00a0al (2008) Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 3: e2409","journal-title":"PLoS One"},{"key":"BFEMMM201707567_CR23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/cas.12208","volume":"104","author":"GD Li","year":"2013","unstructured":"Li GD, Kawashima H, Ogose A, Ariizumi T, Hotta T, Kuwano R, Urata Y, Fujiwara T, Endo N (2013) Telomelysin shows potent antitumor activity through apoptotic and non\u2010apoptotic cell death in soft tissue sarcoma cells. Cancer Sci 104: 1178\u20131188","journal-title":"Cancer Sci"},{"key":"BFEMMM201707567_CR202","doi-asserted-by":"crossref","first-page":"e0177810","DOI":"10.1371\/journal.pone.0177810","volume":"12","author":"N Marino","year":"2017","unstructured":"Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN (2017) Development of a versatile oncolytic virus platform for local intra\u2010tumoural expression of therapeutic transgenes. PLoS One 12: e0177810","journal-title":"PLoS One"},{"key":"BFEMMM201707567_CR24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","volume":"17","author":"TR Mosmann","year":"1996","unstructured":"Mosmann TR, Sad S (1996) The expanding universe of T\u2010cell subsets: Th1, Th2 and more. Immunol Today 17: 138\u2013146","journal-title":"Immunol Today"},{"key":"BFEMMM201707567_CR25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/icb.2016.126","volume":"95","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Smyth MJ (2016) Targeting cancer\u2010related inflammation in the era of immunotherapy. Immunol Cell Biol 95: 325\u2013332","journal-title":"Immunol Cell Biol"},{"key":"BFEMMM201707567_CR26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single\u2010chain antibody constructs on MHC class I\u2010negative tumor cells. Mol Immunol 43: 763\u2013771","journal-title":"Mol Immunol"},{"key":"BFEMMM201707567_CR27","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau\u2010Chacon R, Chiu HJ, Gehrke BJ, Gomez\u2010Broughton C, Kane RC, Kirshner S et\u00a0al (2015) FDA approval: blinatumomab. Clin Cancer Res 21: 4035\u20134039","journal-title":"Clin Cancer Res"},{"key":"BFEMMM201707567_CR28","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.4049\/jimmunol.176.12.7308","volume":"176","author":"MA Purbhoo","year":"2006","unstructured":"Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jager E, Cameron BJ, Lissin N et\u00a0al (2006) Quantifying and imaging NY\u2010ESO\u20101\/LAGE\u20101\u2010derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176: 7308\u20137316","journal-title":"J Immunol"},{"key":"BFEMMM201707567_CR29","doi-asserted-by":"crossref","first-page":"e0136417","DOI":"10.1371\/journal.pone.0136417","volume":"10","author":"IM Schellens","year":"2015","unstructured":"Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans\u2010van den Brink JA, van der Poel K, Costa AI, van Els CA, van Baarle D et\u00a0al (2015) Comprehensive analysis of the naturally processed peptide repertoire: differences between HLA\u2010A and B in the immunopeptidome. PLoS One 10: e0136417","journal-title":"PLoS One"},{"key":"BFEMMM201707567_CR30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","volume":"114","author":"LW Seymour","year":"2016","unstructured":"Seymour LW, Fisher KD (2016) Oncolytic viruses: finally delivering. Br J Cancer 114: 357\u2013361","journal-title":"Br J Cancer"},{"key":"BFEMMM201707567_CR31","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA et\u00a0al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine\u2010directed therapy. Blood 121: 5154\u20135157","journal-title":"Blood"},{"key":"BFEMMM201707567_CR32","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M et\u00a0al (2011) Targeted therapy with the T\u2010cell\u2010engaging antibody blinatumomab of chemotherapy\u2010refractory minimal residual disease in B\u2010lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia\u2010free survival. J Clin Oncol 29: 2493\u20132498","journal-title":"J Clin Oncol"},{"key":"BFEMMM201707567_CR33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.yexmp.2012.09.018","volume":"93","author":"P Weerasinghe","year":"2012","unstructured":"Weerasinghe P, Buja LM (2012) Oncosis: an important non\u2010apoptotic mode of cell death. Exp Mol Pathol 93: 302\u2013308","journal-title":"Exp Mol Pathol"},{"key":"BFEMMM201707567_CR34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","volume":"10","author":"E Wolf","year":"2005","unstructured":"Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA (2005) BiTEs: bispecific antibody constructs with unique anti\u2010tumor activity. Drug Discov Today 10: 1237\u20131244","journal-title":"Drug Discov Today"},{"key":"BFEMMM201707567_CR35","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1002\/ijc.28312","volume":"133","author":"X Yao","year":"2013","unstructured":"Yao X, Labelle M, Lamb CR, Dugan JM, Williamson CA, Spencer DR, Christ KR, Keating RO, Lee WD, Paradis GA et\u00a0al (2013) Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24\u00a0as a marker of disseminated tumor cells. Int J Cancer 133: 2925\u20132933","journal-title":"Int J Cancer"},{"key":"BFEMMM201707567_CR36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cpt.651","volume":"101","author":"T Yuraszeck","year":"2017","unstructured":"Yuraszeck T, Kasichayanula S, Benjamin JE (2017) Translation and clinical development of bispecific T cell engaging antibodies for cancer treatment. Clin Pharmacol Ther 101: 634\u2013645","journal-title":"Clin Pharmacol Ther"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201707567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.201707567","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.201707567\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.201707567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201707567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:24:41Z","timestamp":1779085481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.201707567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,1]]}},"alternative-id":["BFEMMM201707567"],"URL":"https:\/\/doi.org\/10.15252\/emmm.201707567","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]},"assertion":[{"value":"11 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D.F. and L.W.S. own equity or share options in PsiOxus Therapeutics, which is leading clinical development of EnAd and its derivatives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}